Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Wierda Discusses the Need for Newer Therapies in CLL

October 11th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for newer therapies in the treatment of chronic lymphocytic leukemia.

Dr. LeBlanc on Incorporating Palliative Care in the Treatment of Hematologic Malignancies

October 11th 2017

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, gives advice on incorporating palliative care in the treatment of hematologic malignancies.

FDA Grants Gilteritinib Fast Track Designation for AML

October 11th 2017

The FDA has granted Fast Track designation to gilteritinib for adult patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia (AML).

Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

October 11th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Dr. Stone Discusses Monitoring MRD in AML

October 11th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.

Dr. Wong Discusses Monoclonal Antibodies in Plasma Cell Neoplasms

October 11th 2017

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses monoclonal antibodies in plasma cell neoplasms.

Mesa Highlights Guideline Updates in Myeloproliferative Neoplasms

October 11th 2017

The National Comprehensive Cancer Network guidelines for the management of polycythemia vera and essential thrombocythemia have been updated to create a more uniform system of management for healthcare providers to follow in clinical practice.

Dr. Callander on Treatment Considerations in Multiple Myeloma

October 10th 2017

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.

TP53 Predicts Poorer Survival in Mantle Cell Lymphoma

October 9th 2017

Multivariate analysis of the Nordic MCL2 and MCL3 trials showed that the presence of TP53 mutations predicted worse overall survival in younger patients with mantle cell lymphoma.

CAR T Cells Highly Successful in ALL

October 9th 2017

Defined composition CAR T cells directed against CD19 have potent anti-tumor activity in B cell malignancies, including acute lymphocytic leukemia.

New AML Drugs Approved and Under Investigation in 2017

October 9th 2017

After nearly 40 years with little in the way of drug development for the treatment of acute myeloid leukemia, four new drugs have been approved by the FDA in 2017 for AML, and several promising agents are in development.

Managing Newly-Diagnosed Multiple Myeloma

October 8th 2017

Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.

Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia

October 8th 2017

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Dr. Winter Discusses Response in Follicular Lymphoma

October 8th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.

New Therapies Being Developed Rapidly for Relapsed Hodgkin Lymphoma

October 8th 2017

In relapsed classical Hodgkin lymphoma, the era of therapies post-brentuximab vedotin is developing rapidly.

Wierda Discusses Novel Combinations, Sequencing in CLL

October 8th 2017

William G. Wierda, MD, PhD, discusses the continued importance of ibrutinib, the promise for novel combinations, and the impact this progress has had on sequencing for CLL.

Data Emerges on Maintenance Therapies, Developing Treatments for Relapsed/Refractory FL

October 8th 2017

Survival for patients with grade 1 to 2 follicular lymphoma is now measured in decades to coincide with improvements in therapy.

Reinduction Regimen Effective in Late Marrow-Relapsed Pediatric ALL

October 6th 2017

In the CALL-0603 study of 44 patients with first marrow-relapsed childhood acute lymphoblastic leukemia, the second complete remission rate was 72.7% for a chemotherapy regimen that included a reduced dose of idarubicin.

Dr. Hofmeister on the Treatment of Patients with Newly Diagnosed Myeloma

October 3rd 2017

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.

Dr. Awan Discusses Venetoclax in CLL

October 3rd 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia.